Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

Hikmat Abdel-Razeq,1,2 Baha’ Sharaf,1 Rama AlMasri,3 Rashid Abdel-Razeq,1 Faris Tamimi,1 Omar Khader,1 Osama Salama,1 Mahmoud Abunasser,1 Sarah Edaily,1 Hazem Abdulelah1 1Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan; 2Department of Internal Medicine, School of Medicine,...

Full description

Bibliographic Details
Main Authors: Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H
Format: Article
Language:English
Published: Dove Medical Press 2022-03-01
Series:Cancer Management and Research
Subjects:
cdk4/6 inhibitors
letrozole
fulvestrant
thrombosis
patient stratification
prediction
Online Access:https://www.dovepress.com/thromboembolic-events-in-patients-with-her2-negative-hormone-receptor--peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/thromboembolic-events-in-patients-with-her2-negative-hormone-receptor--peer-reviewed-fulltext-article-CMAR

Similar Items